Analytical Data
-
Gene name
CYP3A7
- Application
-
Alternative Names
CP37; P450-HFLA; Cytochrome P450,Family 3,Subfamily A,Polypeptide 7
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P24462
-
Expression Region
Pro344~Asp497
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A7 is a member of the cytochrome P450 superfamily of enzymes, primarily expressed in the liver and the extrahepatic tissues, including the intestine and adrenal glands. It plays a crucial role in the metabolism of various endogenous and exogenous compounds, including hormones, drugs, and environmental toxins. Unlike its closely related isoforms CYP3A4 and CYP3A5, CYP3A7 exhibits a unique expression pattern, being predominantly active during fetal development and diminishing after birth. This enzymatic activity raises significant interest in pharmacogenomics, as variations in CYP3A7 expression can influence drug metabolism, efficacy, and toxicity in different populations. Studies have shown that polymorphisms in the CYP3A7 gene can lead to altered enzyme activity, impacting the pharmacokinetics of medications metabolized by this pathway. Furthermore, the study of CYP3A7's role in drug interactions and its potential implications in therapeutic drug monitoring has become increasingly relevant, particularly for pregnant women and pediatric patients. The reconstitution of CYP3A7 in vitro allows for detailed characterization of its enzymatic properties and substrate specificity, enabling researchers to better understand its function and relevance in drug metabolism. This knowledge is essential for developing personalized medicine strategies and optimizing drug therapy based on individual genetic makeup. The research on CYP3A7 could unveil new insights into metabolic pathways and contribute to safer, more effective pharmacological care tailored to the needs of diverse patient populations.
